2. Academic Validation
  3. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

  • Cancer Res. 2022 Sep 16;82(18):3375-3393. doi: 10.1158/0008-5472.CAN-21-4222.
Russell Moser 1,  James Annis 2,  Olga Nikolova 3,  Cliff Whatcott 4,  Kay Gurley 1,  Eduardo Mendez 5,  Kim Moran-Jones 6,  Craig Dorrell 7,  Rosalie C Sears 7,  Calvin Kuo 8,  Haiyong Han 4,  Andrew Biankin 4,  Carla Grandori 9,  Daniel D Von Hoff 4,  Christopher J Kemp 1
Affiliations

Affiliations

  • 1 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 2 Quellos High Throughput Facility, Institute for Stem Cell and Regenerative Medicine, University of Washington Medicine Research, Seattle, Washington.
  • 3 Department of Computational Biology, Oregon Health and Science University, Portland, Oregon.
  • 4 Translational Genomics Research Institute, Molecular Medicine Division, Phoenix, Arizona.
  • 5 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • 6 Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • 7 Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon.
  • 8 Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California.
  • 9 SEngine Precision Medicine, Seattle, Washington.
PMID: 35819261 DOI: 10.1158/0008-5472.CAN-21-4222
Abstract

This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce Apoptosis in KRAS-driven pancreatic Cancer.

Figures
Products